Does Rallies show Form 4 insider transactions for TYRA?

Yes. Rallies tracks TYRA insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is TYRA research on Rallies investment advice?

No. Rallies provides research, data, and educational context for TYRA. It does not provide personalized investment advice.

TYRA (Tyra Biosciences, Inc. Common Stock) Stock Analysis - Insider Trades

Tyra Biosciences, Inc. Common Stock (TYRA) is a publicly traded Healthcare sector company. As of May 21, 2026, TYRA trades at $33.15 with a market cap of $2.12B and a P/E ratio of -16.75. TYRA moved -1.04% today. Year to date, TYRA is +27.04%; over the trailing twelve months it is +234.67%. Its 52-week range spans $6.42 to $40.65. Analyst consensus is strong buy with an average price target of $50.30. Rallies surfaces TYRA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading TYRA stock inside the company?

Recent TYRA insider activity includes KAPLAN GILLA sold 14.29K, Bensen Daniel sold 2.13K, Bensen Daniel sold 5.87K, Bensen Daniel sold 6.98K, and Bensen Daniel sold 1.02K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

TYRA Key Metrics

Key financial metrics for TYRA
Metric	Value
Price	$33.15
Market Cap	$2.12B
P/E Ratio	-16.75
EPS	$-2.01
Dividend Yield	0.00%
52-Week High	$40.65
52-Week Low	$6.42
Volume	0
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-119.95M
Gross Margin	0.00%

Recent TYRA Insider Trades

KAPLAN GILLA sold 14.29K (~$528.51K) on Mar 25, 2026.
Bensen Daniel sold 2.13K (~$67.04K) on Feb 12, 2026.
Bensen Daniel sold 5.87K (~$195.93K) on Feb 12, 2026.
Bensen Daniel sold 6.98K (~$198.61K) on Jan 12, 2026.
Bensen Daniel sold 1.02K (~$29.58K) on Jan 12, 2026.

Latest TYRA News

Tyra Biosciences Holds $383.5M Cash, Doses First Patient in SURF303 — May 13, 2026
Tyra Biosciences Appoints Habib Dable to Board to Advance Dabogratinib Commercialization — Apr 17, 2026
Tyra Biosciences Raises $256M Cash, Eyes SURF302 and BEACH301 Data in 2026 — Mar 2, 2026
Tyra Biosciences Sees >70% NMIBC CR Rate by Mid-Year, Advances UTUC Trial — Mar 2, 2026

TYRA Analyst Consensus

13 analysts cover TYRA: 0 strong buy, 13 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $50.30.

Common questions about TYRA

Who is trading TYRA stock inside the company?: Recent TYRA insider activity includes KAPLAN GILLA sold 14.29K, Bensen Daniel sold 2.13K, Bensen Daniel sold 5.87K, Bensen Daniel sold 6.98K, and Bensen Daniel sold 1.02K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for TYRA?: Yes. Rallies tracks TYRA insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is TYRA research on Rallies investment advice?: No. Rallies provides research, data, and educational context for TYRA. It does not provide personalized investment advice.